Eiko Lifesciences to Acquire 51% of SSM Formulations, Raising Funds via Warrants and Equity Shares

Eiko Lifesciences Ltd. has announced the acquisition of 51% equity shares of M/s. SSM Formulations Private Limited, a company operating in the pharmaceuticals business. The acquisition will make SSM Formulations a subsidiary of Eiko LifeSciences Limited. The company also plans to raise funds through the issue and allotment of warrants and equity shares. The acquisition is a strategic forward-integration move into pharmaceutical formulations, aimed at diversifying the product portfolio and capturing higher value across the pharmaceutical supply chain. The transaction is expected to generate operational synergies and economies of scale, and the target entity's business aligns directly with the Company's core line of activity.